Pasithea Therapeutics (KTTA) Return on Capital Employed (2021 - 2026)
Pasithea Therapeutics recorded quarterly Return on Capital Employed of 38.82% in Q1 2026, up 40.51% quarter-over-quarter from 65.26% in Q4 2025, and up 6207.0% year-over-year from 0.62% in Q1 2025.
Pasithea Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 38.82% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6207.0% year-over-year to 38.82%; the TTM figure through Mar 2026 stood at 38.82% (up 6207.0% YoY), while the FY2025 annual figure was 62.86%, up 849.0% from the prior year.
- Return on Capital Employed came in at 38.82% for Q1 2026 at Pasithea Therapeutics, up from 65.26% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.29% in Q1 2022 to a low of 100.89% in Q1 2025.
- A 5-year average of 59.35% and a median of 62.05% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 5134 bps in 2024 and soared 6207 bps in 2026, its largest moves.
- Pasithea Therapeutics' Return on Capital Employed stood at 28.37% in 2022, then slumped by 119 bps to 62.05% in 2023, then sank by 41 bps to 87.79% in 2024, then grew by 26 bps to 65.26% in 2025, then soared by 41 bps to 38.82% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 38.82%, 65.26%, and 99.41% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -38.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.82% |
| Dec 31, 2025 | -65.26% |
| Sep 30, 2025 | -99.41% |
| Jun 30, 2025 | -97.57% |
| Mar 31, 2025 | -100.89% |
| Dec 31, 2024 | -87.79% |
| Sep 30, 2024 | -92.28% |
| Jun 30, 2024 | -90.79% |
| Mar 31, 2024 | -77.11% |
| Dec 31, 2023 | -62.05% |
| Sep 30, 2023 | -45.96% |
| Jun 30, 2023 | -39.45% |
| Mar 31, 2023 | -33.07% |
| Dec 31, 2022 | -28.37% |
| Sep 30, 2022 | -21.74% |
| Jun 30, 2022 | -16.14% |
| Mar 31, 2022 | -12.29% |
| Dec 31, 2021 | -12.27% |